



PRESS RELEASE

This information was submitted for publication on 19 July 2018 at 15.30 CET.

Probi CFO to resign

Probi AB (publ) (“Probi”) announces that Jörn Andreas will leave his position as CFO tentatively as per 31 December 2018, or such earlier or later date when a new CFO can take office. The request to leave is made for personal reasons.

“Jörn Andreas has been a highly appreciated and valued member of group management and, previously, board member of Probi. We regret that he has decided to move back to Germany”, says chairman of the board Jean-Yves Parisot.

The board has initiated a process to recruit a new CFO.

This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 19 July 2018 at 15.30 CET.

FOR FURTHER INFORMATION, CONTACT:

Jean-Yves Parisot, Chairman of the Board, Probi, tel +33 670 48 0684, e-mail: ir@probi.se
Niklas Brandt, CIO & Investor Relations, Probi, tel +46 46 286 89 26, e-mail: niklas.brandt@probi.com

ABOUT PROBI

Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2017, Probi had net sales of MSEK 612. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at www.probi.com.